Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Inclusion Criteria: Patients aged 20 or older at the time of writing the informed consent H. pylori-positive patient. Patients who are diagnosed with gastric ulcer by endoscopy and have the following ulcer characteristics; Non-scarring ulcer (stage A1, A2, H1, H2 according to the Sakita-Miwa classification), Single ulcer, Ulcer size of 5 to 20mm in diameter Exclusion Criteria: Patients who previously underwent H. pylori eradication therapy Malignant gastric ulcer Linear ulcer Patients with history of upper GI tract resection or vagotomy Patients with continuous NSAIDs use within 4 weeks prior to study initiation Patients with ulcer complications including perforation or pyloric stenosis Gastric ulcer prone to bleeding (e.g. exposed blood vessels at ulcer base) Patients with infectious mononucleosis Patients with known hypersensitivity to penicillin, clarithromycin, omeprazole, amoxicillin or rebamipide Patients on medications such as terfenadine or pimozide which are contraindicated with clarithromycin usage Pregnant or possibly pregnant women, lactating women, or those with a plan to conceive during this study Blood test results of Hb ≤ 8.0 g/dl, platelet ≤50,000 /㎕, total WBC ≤ 4000/㎕ or ≥ 10,000/㎕, and with serum test results showing the levels of AST, ALT, ALP, LDH, BUN, and creatinine exceeding twice the normal range of respective institution. Other patients deemed not eligible for this study by investigators